Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Iterion Therapeutics

Request full access

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company

Houston, United StatesFounded 2014Biotech & Life Sciences

About Iterion Therapeutics

Iterion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The company's lead product, Tegavivint, is a potent and selective inhibitor of transducin beta-like protein 1 (TBL1), a key component of the Wnt beta-catenin signaling pathway. Dysregulation of this pathway is associated with increased nuclear activity that activates genes linked to cancer and fibrosis. Iterion Therapeutics is currently enrolling patients in a Phase 1 clinical study of Tegavivint for the treatment of desmoid tumors, a rare and aggressive type of tumor. The company operates in the biopharmaceutical market, targeting oncologists and healthcare providers who treat cancer and fibrotic diseases. Iterion's business model involves the development and commercialization of its proprietary therapies, generating revenue through product sales, partnerships, and licensing agreements. The company aims to bring innovative treatments to patients with high unmet medical needs.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
36.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Feb 2021 $17M $68M Viva BioInnovator · Venture Investors Health Fund · GPG Ventures · Lumira Ventures —
SERIES B✓Equity / VC Jun 2018 $2.6M $10M Sante Ventures · angelMD —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Iterion Therapeutics website traffic

Latest recorded traffic for Iterion Therapeutics is 590 monthly website visits, down 37.2% over the last three months. Iterion Therapeutics's team grew 6.7% over the past year.

Latest monthly visits590 3-month web change-37.2% 1-year team growth+6.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Iterion Therapeutics in the Houston ecosystem

Live from Dealroom

The Iterion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Sante Ventures
  • angelMD
  • Lumira Ventures
  • Viva BioInnovator
  • Venture Investors Health Fund
  • GPG Ventures

Other known investors3 additional known investors

  • Huntsman Cancer Institute
  • University of Utah
  • GOOSE Capital
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States92.3%
🇨🇦 Canada7.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Iterion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Iterion Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.